Status:
RECRUITING
DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML
Lead Sponsor:
Affiliated Hospital to Academy of Military Medical Sciences
Conditions:
High-risk Soft Tissue Sarcoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The aim of this Phase Ⅰ/Ⅱ study is to evaluate the safety and efficacy of dendritic cells (DCs) vaccine combined with cytokine-induced killer (CIK) cells in patients with AML. Experimental recombinant...
Eligibility Criteria
Inclusion
- Consistent with the diagnosis of AML
- Age≥18 years at time of consent
- KPS(Karnofsky Performance Scale) ≥70
- Patient's written informed consent
- No steroid therapy within 4 weeks of first DC vaccination
- Stable disease, complete response and partial response(WHO, RECIST)
- Predicted survival≥3 months
Exclusion
- Serious dysfunction of vital organs(heart, liver or kidney)
- Received organ transplantation
- Patients with other malignancies or brain metastases
- History of autoimmune diseases
- Pregnant and breast-feeding patient
- Active or chronic infectious diseases
- History of allergy or hypersensitivity to study product excipients
- Currently participating in another clinical trial
- Received chemotherapy, radiotherapy, immune inhibitor (such as corticosteroid) or other immunotherapy (such as vaccine) during prior 4 weeks
- Unfit for participating in this clinical trial in investigators' opinions
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01898663
Start Date
June 1 2013
End Date
December 30 2024
Last Update
July 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematopoietic Stem Cell Transplantation
Beijing, China, 100071